Moderna announces that the effectiveness of the vaccine in the Phase III trial of Covid-19 reaches 94.5%

Moderna (16th) issued a statement on Twitter on Monday, saying that preliminary analysis of data from more than 30,000 American volunteers showed that Moderna’s vaccine mRNA-1273 actually prevented all symptomatic Covid-19 caused by the new coronavirus. Case. Moderna expects to produce 500 million to 1 billion doses of the new crown vaccine globally in 2021.

It is reported that 95 cases of confirmed new coronavirus infection among 30,000 subjects were evaluated, and the effectiveness of the vaccine was proved to be 94.5%. The company also stated that no serious safety issues have been found, and the vaccine is generally safe and well tolerated. Among them, most of the adverse reactions of the subjects were mild or moderate, and the side effects mainly included pain at the injection site, fatigue, muscle pain and headache.

Moderna said in the report that its new crown vaccine has a longer shelf life, and the vaccine can be stable for 30 days at a refrigerator temperature; it can be stored for up to 6 months at -20°C. It plans to apply to the United States for emergency use of the new crown vaccine in the next few weeks, and also submit the new crown vaccine to other global regulatory agencies for authorization.

© 2020, . Disclaimer: The part of contents and images are collected and revised from Internet. Contact us ( immidiatly if anything is copyright infringed. We will remove accordingly. Thanks!